-
17β-HSD Related Products (144)
Related Products (144)
-
HSD17B13-IN-31
0 ImagesCat. No.: HY-161224CAS No.: 2758802-33-2HSD17B13-IN-31 (compound 32) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM and? ＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-31? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis).
-
HSD17B13-IN-42
0 ImagesCat. No.: HY-161226CAS No.: 2770246-10-9HSD17B13-IN-42 (compound 10)? is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-42? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis).
-
HSD17B13-IN-37
0 ImagesCat. No.: HY-163248CAS No.: 2770246-71-2HSD17B13-IN-37 (78) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
-
HSD17B13-IN-102
0 ImagesCat. No.: HY-161278CAS No.: 2770246-34-7HSD17B13-IN-100 (compound 37) is an inhibitor of HSD17B13 and has IC50 with Estradiol ＜0.1 μM.
-
(±)-Naproxen (Standard)
0 ImagesSynonyms: (Rac)-Naproxen (Standard)(±)-Naproxen (Standard) ((Rac)-Naproxen (Standard)) is the analytical standard of (±)-Naproxen (HY-15029). This product is intended for research and analytical applications. (±)-Naproxen is the racemate of Naproxen (HY-15030), consisting of R- and S-enantiomers. (±)-Naproxen binds to AKR1C3, which preferentially recognizes the R-enantiomer from the racemic mixture. It is used for AKR1C3 stereoselective ligand recognition and studies on NSAID binding mechanisms.
-
S34-1035
0 ImagesCat. No.: HY-184927CAS No.: 3099381-65-1
-
HSD17B13-IN-16
0 ImagesCat. No.: HY-161217CAS No.: 2758802-09-2HSD17B13-IN-16 (compound 8) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM and? ＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-16? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis).
-
HSD17B13-IN-35
0 ImagesCat. No.: HY-163247CAS No.: 2770246-69-8HSD17B13-IN-35 (compound 76) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-35? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis).
-
HSD17B13-IN-63
0 ImagesCat. No.: HY-162209CAS No.: 2770247-51-1HSD17B13-IN-63 (Compound 160) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-63 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
-
HSD17B13-IN-57
0 ImagesCat. No.: HY-163254CAS No.: 2770246-86-9HSD17B13-IN-57 (Compound 93) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-57 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
-
HSD17B13-IN-28
0 ImagesCat. No.: HY-163242CAS No.: 2770246-42-7HSD17B13-IN-28 (compound? 47) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-28? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis).
-
HSD17B13-IN-100
0 ImagesCat. No.: HY-161277CAS No.: 2770246-33-6HSD17B13-IN-100 (compound 34) is an inhibitor of HSD17B13 and has IC50 with estradiol ＜0.1 μM.
-
HSD17B13-IN-80
0 ImagesCat. No.: HY-163263CAS No.: 2770247-42-0HSD17B13-IN-80 (Compound 151) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-80 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
-
HSD17B13-IN-44
0 ImagesCat. No.: HY-157667CAS No.: 2912452-29-8HSD17B13-IN-44 (Compound 23) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-44 can be used for research on liver diseases or metabolic disorders.
-
HSD17B13-IN-45
0 ImagesCat. No.: HY-157671CAS No.: 2912452-50-5HSD17B13-IN-45 (Compound 195) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-45 can be used for research on liver diseases or metabolic disorders.
-
HSD17B13-IN-106
0 ImagesCat. No.: HY-159662CAS No.: 3035000-69-9HSD17B13 degrader 2 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). HSD17B13 degrader 2 can be used for synthesis PTOTAC HSD17B13 degrader 1 (HY-159651).
-
HSD17B13-IN-81
0 ImagesCat. No.: HY-163264CAS No.: 2770247-45-3HSD17B13-IN-81 (Compound 154) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-81 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
-
HSD17B13-IN-40
0 ImagesCat. No.: HY-161225CAS No.: 2770246-06-3HSD17B13-IN-40 (compound 6) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-40? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis).
-
HSD17B13-IN-58
0 ImagesCat. No.: HY-163255CAS No.: 2770246-89-2HSD17B13-IN-58 (96) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
-
HSD17B13-IN-33
0 ImagesCat. No.: HY-157662CAS No.: 2730027-85-5HSD17B13-IN-33 (Compound 115) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-33 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
